ViaGen Pets & Equine

Based in the US, ViaGen LC. dba ViaGen Pets & Equine specializes in genetic preservation and animal cloning services, focusing on pets like dogs, cats, and horses, helping owners recreate their beloved companions after loss. Founded in 2002 in the United States, ViaGen Pets & Equine offers genetic preservation and cloning services for pets. The company has not reported any significant pivots in its business strategy.

As of November 2025, the firm was acquired by Colossal Biosciences Inc. , which aims to integrate ViaGen's cloning technology into its de-extinction platform. The founder's specific history is not detailed in the provided information. ViaGen Pets & Equine specializes in genetic preservation and cloning services for animals, primarily focusing on pets such as dogs, cats, and horses.

The company's core offerings include advanced cloning technology and genetic preservation solutions that allow pet owners to recreate their beloved animals after loss. The cloning process utilizes sophisticated animal biotechnology to replicate genetic material, ensuring precision and reliability in replicating the pet's genetic makeup. ViaGen serves a diverse client base that includes individual pet owners, major conservation institutions, and veterinary professionals across North America and select international markets, providing solutions that cater to emotional bonds between pet owners and their companions while also contributing to species conservation efforts. Their services target both personal companionship and the scientific community's conservation needs, addressing the desire for continuity in the lives of pet owners and the preservation of genetic diversity in endangered species.

ViaGen Pets & Equine generates revenue through direct-to-consumer transactions for its cloning and genetic preservation services. Clients typically engage in a process that starts with ordering genetic preservation biopsy kits, followed by various stages of consultation and service, culminating in the cloning of their animals. The company’s transaction structure emphasizes a personalized experience, with clients receiving detailed guidance and support throughout the cloning process. Revenue is derived from the fees associated with genetic preservation and cloning services, with specific pricing plans tailored to the uniqueness of each pet's genetic material and the cloning process involved.

ViaGen's flagship services encompass both individual cloning projects and partnerships with conservation organizations, allowing for a multifaceted revenue approach that combines personal pet services with broader ecological goals. In November 2025, ViaGen Pets & Equine was acquired by Colossal Biosciences Inc. , which plans to integrate its cloning technology into its conservation efforts. This acquisition is expected to support ViaGen's initiatives in expanding its cloning services and genetic preservation technology.

Specific future products and their release timelines have not been disclosed, but the integration into Colossal's platform suggests a broader application of its technology in conservation. Recently acquired funding will be directed towards enhancing these efforts, although specific financial terms were not disclosed.